<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485979</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10073</org_study_id>
    <secondary_id>EudraCT 2006-006473-24</secondary_id>
    <nct_id>NCT00485979</nct_id>
  </id_info>
  <brief_title>Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients</brief_title>
  <acronym>SATIN</acronym>
  <official_title>A Randomized, Open-label, Multi-center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-operative Therapy in Patients With High Risk Localized Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the pathological Complete Response (pCR)
      rate by treatment arm (according to Chevallier criteria).

      The secondary objectives are:

        -  to assess in each treatment arm the clinical Response Rate (RR), the rate of breast
           conservation, the Progression-Free Survival (PFS), the Overall Survival (OS), the safety
           and tolerability profile, the pathological Complete Response rate (pCR) according to
           NSABP and Sataloff criteria,

        -  to rank docetaxel and larotaxel alone in Her2 -ve patients, or combined with trastuzumab
           in Her2 +ve patients, according to the pCR rate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response will be assessed according to Chevallier criteria for patients who underwent surgery.</measure>
    <time_frame>treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate, Rate of breast conservation, Progression-Free Survival, Overall Survival, pathological response according to NSABP and Sataloff criteria for patients who underwent surgery</measure>
    <time_frame>treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability profile</measure>
    <time_frame>treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Her2-ve breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 1: Her2-ve breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Her2+ve breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 2: Her2+ve breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>larotaxel (XRP9881)</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>Arm A1</arm_group_label>
    <arm_group_label>Arm A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>Arm B1</arm_group_label>
    <arm_group_label>Arm B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>intravenous administration</description>
    <arm_group_label>Arm A2</arm_group_label>
    <arm_group_label>Arm B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven invasive breast adenocarcinoma

          -  Localized breast cancer: stage II and III

          -  Tumors clinically palpable and ineligible for breast conservative surgery: unifocal
             tumor with diameter â‰¥ 3cm (clinical examination) or central unifocal tumor, or whose
             characteristics make pre-operative chemotherapy mandatory due to high risk factors
             (i.e. ipsilateral lymph nodes involvement, rapid growth rate)

          -  After 30 June 2008, known status for Her2neu by immunohistochemistry (IHC) or by
             fluorescent in situ hybridization (FISH)

        Exclusion Criteria:

          -  Bilateral and inflammatory breast cancer

          -  Abnormal Left Ventricular Ejection Fraction

          -  Distant metastases or locoregional relapse

          -  Inadequate organ functions

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Marty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Therapeutic Innovations in Oncology and Haematology / Saint Louis University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Megrine</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Montevideo</city>
        <country>Uruguay</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
    <country>Uruguay</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2007</study_first_submitted>
  <study_first_submitted_qc>June 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2007</study_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Neoadjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

